As new technologies and personalized vaccines become the norm, the dynamic of clinical trials has to evolve. This focused clinical development conference will allow you to showcase your services to those who are looking to run new trial models, need support in choosing and gaining approval for different clinical endpoints and want to understand how to get the best out of the information collected.
• National and International Government
• Academics And Research Institutions
• CEO / CSO / COO
• CMO / Head of Scientific Affairs
• Head of Clinical Development
• Head of Clinical Trial Management / Operations
• Head of R&D
Who Should Sponsor?
• OEMs / Equipment Manufacturers
• Platform Technology Providers
• Big Pharma
Clinical Development and Trials Conference, Tuesday 16 April 2019
- Immunology and virology of HIV-1 infection and developing novel vaccine strategies
Seasonal influenza vaccine efficacy studies: Lessons learned from 3 global studies
Overcoming challenges in seasonal vaccine studies
Conceptualizing issues around routes of inoculation VS immunological response
Comparison of Zika Virus Neutralization Assay Platforms: PRNT and RVP
Wayne Hogrefe, Vice President, Vaccines, Q² Solutions
NanoQuil - a novel next-generation saponin adjuvant
Correlates of Protection in Vaccine Clinical Development
-From Model Fitting to Machine Learning
Frontiers in controlled human malaria infection (CHMI): accelerating malaria vaccine development, use in HIV+ populations, and empowering malaria research in Africa
-Aseptic, purified, cryopreserved sporozoites for CHMI (“challenge in a bottle”)-Expansion of research capabilities in Africa-Ethical considerations of CHMI in HIV+ populations
How do we move forward in Zika vaccine development using the Human Challenge Model
-Bioethics of using the human challenge model-Background information on the original report for zika vaccine development-Epidemiology of zika today-How has the landscape changed
-How are the studies done?-How are the models developed and used?-How are CHIMS becoming more commercially used?-Why do subjects volunteer?
Philip Krause, Deputy Director, U.S. Food and Drug Administration
last published: 14/Dec/18 13:15
Clinical Development and Trials Conference, Wednesday 17 April 2019
Are bacterial vaccines harder to develop?
- What are the challenges in clinical efficacy trials?
- Phase II Clostridium difficile vaccine
Broad spectrum pneumococcal conjugate vaccines in development
Chair's opening remarks
- What have we learnt from previous vaccines failures to drive new vaccines forward?
- Why is there is low uptake on currently available vaccines? E.g. HPV & influenza
- Examples and case studies from: Lyme & Rota – what does this mean for future vaccine innovation and R&D?
A framework for a comprehensive maternal immunization platform
- Evidence for current immunization recommendations
- Maternal vaccines in development
- The need for evidence-based interventions at the practice, provider, and patient levels to ensure higher vaccination levels
- An industry pipeline dissection
- Which type of companies are engaged in these programs?
- Where will the innovation come from?
- Incentives, insights and potential solutions
last published: 14/Dec/18 13:15